Modern name, purpose, and visual identity mark
inspiring next chapter for maker of iconic, trusted brands,
including Tylenol, Neutrogena, Listerine, and Band-Aid Brand
Johnson & Johnson (the “Company”) (NYSE: JNJ) today took
another step forward in establishing two independent,
market-leading companies with the announcement of Kenvue as the
name for the planned New Consumer Health Company. The new corporate
brand comes to life through a compelling purpose, and a timeless
visual brand.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20220928005340/en/
Kenvue (pronounced ken·view), is inspired by two powerful ideas:
“ken” – meaning knowledge, an English word primarily used in
Scotland, and “vue,” referencing sight. With rich knowledge of
human needs and deep consumer insights, Kenvue will deliver
meaningful, personal health solutions.
“Unveiling the Kenvue brand is a defining moment for our
stakeholders and an important part of the planned separation,” said
Thibaut Mongon, CEO Designate, Kenvue, the planned New Consumer
Health Company. “We breathe life into some of the world’s most
iconic and beloved brands every day, so we harnessed that same
expertise, love, and energy into developing our new corporate
identity.”
Kenvue’s purpose, Realize the Extraordinary Power of Everyday
Care, will guide the company’s actions and long-term aspirations,
from strategy to talent philosophy, and more.
“We believe that daily self-care rituals add up over time and
have a profound cumulative impact on your wellbeing. This is the
extraordinary power of everyday care. And our work is to put that
power into the hands of consumers around the world,” Mongon
adds.
Along with the name and purpose, Kenvue’s visual identity
represents the company’s timelessness, while allowing space for its
iconic brands to also have a home. The new logo centers on the “K”
symbol, embodying the company’s strengths – the geometry of the
rectangle representing scientific precision and the round edges
evoking the warmth of care. The corporate name is depicted in a
distinctive logotype in a rich green. This strong, distinctive
color works in harmony with the multicolored palette of the
company’s portfolio of well-known brands.
Joaquin Duato, Chief Executive Officer of Johnson & Johnson
adds, “Today’s announcement is another milestone for the Consumer
Health business. Kenvue is poised to thrive as a standalone company
with a leading portfolio of brands consumers love and trust. I’m
confident in this team and excited to see what the future
holds.”
Kenvue Post-Separation: A Leading Global Consumer Health
Company with Iconic Brands and Commitment to Continued
Innovation
Kenvue will become a standalone leading global consumer health
company in 2023, subject to legal requirements including
consultation with works councils and employee representatives, as
required. Kenvue will continue to touch the lives of over one
billion consumers worldwide every day through its iconic portfolio
of beloved brands such as AVEENO®, BAND-AID® Brand Adhesive
Bandages, LISTERINE®, NEUTROGENA®, TYLENOL®, JOHNSON’S® and DR.
CI:LABO®, and will continue its longstanding legacy of
innovation.
Usage of the new company logo and corporate brand identity will
be effective upon completion of the planned separation. More
information regarding Kenvue, including the company’s board of
directors and financial transaction information will be available
at a later date.
The Consumer Health segment generated revenue of $14.6 billion
in Full-Year 2021 and, following the planned separation, Kenvue
would generate sales in over 100 countries, driven by world-class
innovation capabilities and demonstrated business momentum.
In recent years, Johnson & Johnson has focused the Consumer
Health business and advanced its innovation, enabling it to reach
more consumers with products that truly make a difference in
peoples’ lives, while simultaneously expanding margins and
delivering healthy financial results. These actions have bolstered
positions in Self Care, Skin Health and Essential Health.
About Johnson &
Johnson
At Johnson & Johnson, we believe good health is the
foundation of vibrant lives, thriving communities and forward
progress. That’s why for more than 135 years, we have aimed to keep
people well at every age and every stage of life. Today, as the
world’s largest and most broadly-based healthcare company, we are
committed to using our reach and size for good. We strive to
improve access and affordability, create healthier communities, and
put a healthy mind, body and environment within reach of everyone,
everywhere. We are blending our heart, science and ingenuity to
profoundly change the trajectory of health for humanity. Learn more
at www.jnj.com. Follow us at @JNJNews.
Cautions Concerning Forward-Looking
Statements
This release contains “forward-looking statements” as defined in
the Private Securities Litigation Reform Act of 1995 regarding,
among other things: the anticipated separation of Johnson &
Johnson’s Consumer Health business; future operating and financial
performance, product development, market position and business
strategy. Readers are cautioned not to rely on these
forward-looking statements. These statements are based on current
expectations of future events. If underlying assumptions prove
inaccurate or known or unknown risks or uncertainties materialize,
actual results could vary materially from the expectations and
projections of Johnson & Johnson. Risks and uncertainties
include, but are not limited to: Johnson & Johnson’s ability to
satisfy the necessary conditions to consummate the separation of
Johnson & Johnson’s Consumer Health business on a timely basis
or at all; Johnson & Johnson’s ability to successfully separate
Johnson & Johnson’s Consumer Health business and realize the
anticipated benefits from the separation; the New Consumer Health
Company’s ability to succeed as a standalone publicly traded
company; economic factors, such as interest rate and currency
exchange rate fluctuations; competition, including technological
advances, new products and patents attained by competitors;
challenges inherent in new product research and development,
including unexpected clinical trial results, additional analysis of
existing clinical data, uncertainty of clinical success and
obtaining regulatory approvals; uncertainty of commercial success
for new and existing products; the impact of business combinations
and divestitures; challenges to patents; the impact of patent
expirations; the ability of Johnson & Johnson to successfully
execute strategic plans, including restructuring plans;
manufacturing difficulties or delays, internally or within the
supply chain; product efficacy or safety concerns resulting in
product recalls or regulatory action; significant adverse
litigation or government action, including related to product
liability claims; changes to applicable laws and regulations,
including tax laws, global health care reforms and import/export
and trade laws; trends toward health care cost containment; changes
in behavior and spending patterns of purchasers of health care
products and services; financial instability of international
economies and legal systems and sovereign risk; increased scrutiny
of the health care industry by government agencies. A further list
and descriptions of these risks, uncertainties and other factors
can be found in Johnson & Johnson’s Annual Report on Form 10-K
for the fiscal year ended January 2, 2022, including in the
sections captioned “Cautionary Note Regarding Forward-Looking
Statements” and “Item 1A. Risk Factors,” in Johnson & Johnson’s
most recently filed Quarterly Report on Form 10-Q and in Johnson
& Johnson’s subsequent filings with the Securities and Exchange
Commission. Copies of these filings are available online at
www.sec.gov, www.jnj.com or on request from Johnson & Johnson.
Any forward-looking statement made in this press release speaks
only as of the date of this press release. Johnson & Johnson
does not undertake to update any forward-looking statement as a
result of new information or future events or developments.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220928005340/en/
Media: media-relations@its.jnj.com
Investor Relations: Jessica Moore +1 732- 524-2955
Lisa Romanko +1 732-524-2034
Johnson and Johnson (NYSE:JNJ)
Historical Stock Chart
From Mar 2024 to Mar 2024
Johnson and Johnson (NYSE:JNJ)
Historical Stock Chart
From Mar 2023 to Mar 2024